FDA Warns on Unapproved Compounded GLP-1 Drugs
The agency says compounded semaglutide and tirzepatide products are not reviewed for safety, effectiveness, or quality before sale.
Updated on Nov. 6, 2026 in Weight Loss
Live Poll
Would you trust a telehealth company to sell you weight loss medication?
The FDA has warned patients and doctors about the risks of unapproved compounded GLP-1 weight loss drugs. The agency also issued warnings to telehealth companies, ingredient suppliers, and outsourcing facilities over retatrutide and cagrilintide compounding.
Why it matters
Compounded versions of semaglutide and tirzepatide are sold without FDA review, and some products carry pharmacy labels that do not exist or falsely use a real pharmacy's name. Patients who buy these products online or through telehealth services may not know what they are actually receiving.
The FDA has received 990 adverse event reports tied to compounded semaglutide and more than 730 tied to compounded tirzepatide as of May 31, 2026. Because many adverse events go unreported, the true count is likely higher than these figures.
The players
U.S. Food and Drug Administration (FDA)
The federal agency responsible for regulating drug safety, effectiveness, and quality in the United States, including compounded medications.
The details
Some compounders are selling salt forms of semaglutide not found in approved drugs, and some telehealth companies ship medication without a doctor screening beforehand. Some compounded shipments have arrived warm or without proper ice packs, and the FDA is aware of counterfeit Ozempic on the market.
Timeline
As of May 31, 2026: the FDA reported 990 adverse event reports tied to compounded semaglutide.
November 6, 2026: the FDA published its warning on unapproved compounded GLP-1 drugs.
Health Landscape
The FDA's warning reflects its ongoing effort to police compounded versions of GLP-1 drugs, which are not subject to the same pre-sale review as approved medications. The agency's focus on telehealth and ingredient suppliers signals enforcement reaching beyond individual prescribers into the broader supply chain.
Patients considering compounded GLP-1 drugs should confirm the product's source and whether a licensed prescriber reviewed their case before purchase. Reporting side effects through FDA MedWatch helps the agency track problems with these products.
The takeaway
Compounded GLP-1 drugs have not been reviewed by the FDA for safety or quality, so checking a product's labeling and prescriber involvement is essential. Reports of adverse events help regulators identify risks that may not yet be visible.
Further reading
Learn more about safe options in our Weight Loss coverage.
More information
Report side effects or problems with compounded drugs through FDA MedWatch adverse event reporting.
Live Poll
Would you trust a telehealth company to sell you weight loss medication?
